Live Breaking News & Updates on Tumor Models

Stay updated with breaking news from Tumor models. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021


Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
-
BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and ....

United Kingdom , United States , Matthew Deyoung , Heather Savelle , Exchange Commission , American Association For Cancer Research , Pediatric Preclinical Testing Consortium , Bicycle Therapeutics , American Association , Cancer Research , Annual Meeting , Bicycle Toxin Conjugates , Nicholas Keen , Chief Scientific Officer , Biomarkers Predictive , Therapeutic Benefit , Immunomodulatory Agents , Molecular Classification , Therapeutic Outcomes , Rapid Accumulation , Cytotoxic Payload , Tumor Tissue Drives , Tumor Models , Novel Drug Delivery Systems , New Drugs , Late Breaking Mini Symposium ,

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021


Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
-
BT7480 to be presented in a New Drugs on the Horizon session; on-track to enter the clinic in 2H 21
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and ....

United States , United Kingdom , Matthew Deyoung , Heather Savelle , Exchange Commission , American Association For Cancer Research , Pediatric Preclinical Testing Consortium , American Association , Cancer Research , Annual Meeting , Bicycle Toxin Conjugates , Nicholas Keen , Chief Scientific Officer , Biomarkers Predictive , Therapeutic Benefit , Immunomodulatory Agents , Molecular Classification , Therapeutic Outcomes , Rapid Accumulation , Cytotoxic Payload , Tumor Tissue Drives , Tumor Models , Novel Drug Delivery Systems , New Drugs , Late Breaking Mini Symposium , Bicycle Toxin Conjugate ,